argenx stock gains on 1,029.50 USD and Kepler PT boost

Published on 09/02/2026 at 09:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

argenx stock trades at 1,029.50 USD after a 0.25 percent 5-day drop, while Kepler Cheuvreux lifted its price view on August 28, 2026.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

argenx SE (NL0010832176) stock traded at 1,029.50 USD on September 2, 2026, after a 0.25 percent 5-day decline and a 2.05 percent gain for 2026, according to MarketScreener. The move came after Kepler Cheuvreux raised its price view on Argenx on August 28, 2026.

Q2 numbers stay the main anchor for investors. The latest cited consensus in the call points to EPS of 2.66 USD and revenue of about 300.61 million USD for the next report, while the previous quarter on Yahoo Finance showed Q2 FY26 EPS of 2.28 USD against an estimate of 1.82 USD and revenue of 481 million USD.

Consensus and valuation

That gap matters because the prior quarter beat was large: EPS topped the estimate by 0.46 USD, and revenue came in above the 400 million USD line. A second valuation signal also came from the same market snapshot, which showed a 52-week range of 61.23 USD to 109.66 USD and an intraday market capitalization of 12.226 billion USD on September 2, 2026.

What the market is pricing

MarketScreener also listed Argenx at 1,029.50 USD on CBOE with a 5-day change of -0.25 percent and a 1st Jan change of +2.05 percent. For investors, that means the stock is still priced close to the top of its recent range while the next earnings update will need to justify the premium.

Go deeper

Argenx investor page

Company filings, updates and investor material for Argenx.

Argenx profile Investor Relations

Vyvgart stays central

Argenx says it is a global immunology company and the first approved neonatal Fc receptor blocker remains the core product line in the company profile on MarketScreener. That product base matters because the market is still valuing the business on the durability of the FcRn franchise rather than on a single quarter.

Price and venue

As of September 2, 2026, Argenx stock was quoted at 1,029.50 USD on CBOE, with a market capitalization of 64.345 billion USD shown in the Yahoo Finance quote snapshot. The 52-week range was 61.23 USD to 109.66 USD, which puts the latest quote far above the lower end and within sight of the upper band.